GKOS
Glaukos Corporation
NYSE · USHealthcareMedical - Devices
$155.46-0.87%
Price as of Jul 20, 2026
GKOS financials
Glaukos Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $507.4M | $383.5M | $314.7M | $282.9M |
| Cost of revenue | $114.2M | $94.0M | $75.6M | $69.0M |
| Gross profit | $393.2M | $289.5M | $239.1M | $213.9M |
| Operating expenses | $479.9M | $411.8M | $367.8M | $296.2M |
| Operating income | -$86.7M | -$122.4M | -$128.7M | -$82.3M |
| Net income | -$187.7M | -$146.4M | -$134.7M | -$99.2M |
| EBITDA | -$146.1M | -$95.6M | -$82.1M | -$48.8M |
| Basic EPS | $-3.28 | $-2.77 | $-2.78 | $-2.09 |
| Diluted EPS | $-3.28 | $-2.77 | $-2.78 | $-2.09 |
| Balance sheet | ||||
| Cash & equivalents | $90.8M | $169.6M | $93.5M | $119.5M |
| Total assets | $893.5M | $974.8M | $940.4M | $1.1B |
| Total liabilities | $237.3M | $207.8M | $478.6M | $544.2M |
| Stockholders’ equity | $656.2M | $766.9M | $461.8M | $530.0M |
| Total debt | $139.6M | $103.4M | $383.7M | $382.9M |
| Net debt | $48.8M | -$66.2M | $290.3M | $263.4M |
| Cash flow | ||||
| Operating cash flow | -$46.3M | -$61.3M | -$57.8M | -$33.1M |
| Capital expenditure | -$7.7M | -$6.3M | -$20.2M | -$30.3M |
| Free cash flow | -$54.0M | -$67.6M | -$78.0M | -$63.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |